Sign inCreate account

Report workspace tools

NCT02713386COMPLETEDanonymous

A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Sponsor

Source record

NRG Oncology

Phase

Source record

Phase I/II

Modality

AI-normalized

small molecule

Target

AI-normalized

Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Indication / condition

AI-normalized

Fallopian Tube Clear Cell Adenocarcinoma

Intervention

Source record

Carboplatin, Paclitaxel, Ruxolitinib Phosphate, Therapeutic Conventional Surgery

Source & freshness

Source record

NCT ID

NCT02713386

Original source

ClinicalTrials.gov

Source last updated

May 25, 2025

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT02713386

Title

A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Sponsor

NRG Oncology

Status

COMPLETED

Phase

Phase I/II

Condition raw

Fallopian Tube Clear Cell Adenocarcinoma

Condition normalized

Fallopian Tube Clear Cell Adenocarcinoma

Modality raw

Fallopian Tube Clear Cell Adenocarcinoma

Modality normalized

small molecule

Target raw

Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Target normalized

Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Interventions

Carboplatin, Paclitaxel, Ruxolitinib Phosphate, Therapeutic Conventional Surgery

Public preview

Source record

This clinical trial evaluates the safety and efficacy of ruxolitinib phosphate in combination with standard chemotherapy (paclitaxel and carboplatin) for patients with advanced-stage epithelial ovarian cancer. The study aims to determine if the addition of ruxolitinib improves progression-free survival compared to chemotherapy alone.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase I/II Study of Ruxolitinib With Front-Line Neoadjuvant and Post-Surgical Therapy in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT02713386

Status

COMPLETED

Phase

Phase I/II

Sponsor

NRG Oncology

Executive brief

Investment-Ready Snapshot

This clinical trial evaluates the safety and efficacy of ruxolitinib phosphate in combination with standard chemotherapy (paclitaxel and carboplatin) for patients with advanced-stage epithelial ovarian cancer. The study aims to determine if the addition of ruxolitinib improves progression-free survival compared to chemotherapy alone.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMay 25, 2025
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02713386

Indication

Fallopian Tube Clear Cell Adenocarcinoma

Modality

small molecule

Target

Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Intervention

Carboplatin, Paclitaxel, Ruxolitinib Phosphate, Therapeutic Conventional Surgery

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.